Literature DB >> 18193048

Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling.

Jean-Pierre Vilardaga1, Viacheslav O Nikolaev, Kristina Lorenz, Sébastien Ferrandon, Zhenjie Zhuang, Martin J Lohse.   

Abstract

Morphine, a powerful analgesic, and norepinephrine, the principal neurotransmitter of sympathetic nerves, exert major inhibitory effects on both peripheral and brain neurons by activating distinct cell-surface G protein-coupled receptors-the mu-opioid receptor (MOR) and alpha2A-adrenergic receptor (alpha2A-AR), respectively. These receptors, either singly or as a heterodimer, activate common signal transduction pathways mediated through the inhibitory G proteins (G(i) and G(o)). Using fluorescence resonance energy transfer microscopy, we show that in the heterodimer, the MOR and alpha2A-AR communicate with each other through a cross-conformational switch that permits direct inhibition of one receptor by the other with subsecond kinetics. We discovered that morphine binding to the MOR triggers a conformational change in the norepinephrine-occupied alpha2A-AR that inhibits its signaling to G(i) and the downstream MAP kinase cascade. These data highlight a new mechanism in signal transduction whereby a G protein-coupled receptor heterodimer mediates conformational changes that propagate from one receptor to the other and cause the second receptor's rapid inactivation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18193048     DOI: 10.1038/nchembio.64

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN: 1552-4450            Impact factor:   15.040


  113 in total

1.  Morphine- and CaMKII-dependent enhancement of GIRK channel signaling in hippocampal neurons.

Authors:  Rounak Nassirpour; Laia Bahima; Arnaud L Lalive; Christian Lüscher; Rafael Luján; Paul A Slesinger
Journal:  J Neurosci       Date:  2010-10-06       Impact factor: 6.167

2.  Microscopy: GPCR dimers moving closer.

Authors:  Manuela Ambrosio; Martin J Lohse
Journal:  Nat Chem Biol       Date:  2010-08       Impact factor: 15.040

Review 3.  On the expanding terminology in the GPCR field: the meaning of receptor mosaics and receptor heteromers.

Authors:  Luigi F Agnati; Diego Guidolin; Jean Pierre Vilardaga; Francisco Ciruela; Kjell Fuxe
Journal:  J Recept Signal Transduct Res       Date:  2010-10       Impact factor: 2.092

4.  Trans-activation between 7TM domains: implication in heterodimeric GABAB receptor activation.

Authors:  Carine Monnier; Haijun Tu; Emmanuel Bourrier; Claire Vol; Laurent Lamarque; Eric Trinquet; Jean-Philippe Pin; Philippe Rondard
Journal:  EMBO J       Date:  2010-11-09       Impact factor: 11.598

5.  Far from the heart: Receptor cross-talk in remote conditioning.

Authors:  Christian Weber
Journal:  Nat Med       Date:  2010-07       Impact factor: 53.440

Review 6.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

7.  G-protein-coupled receptor heteromer dynamics.

Authors:  Jean-Pierre Vilardaga; Luigi F Agnati; Kjell Fuxe; Francisco Ciruela
Journal:  J Cell Sci       Date:  2010-12-15       Impact factor: 5.285

8.  Dynamic Na+-H+ exchanger regulatory factor-1 association and dissociation regulate parathyroid hormone receptor trafficking at membrane microdomains.

Authors:  Juan A Ardura; Bin Wang; Simon C Watkins; Jean-Pierre Vilardaga; Peter A Friedman
Journal:  J Biol Chem       Date:  2011-08-08       Impact factor: 5.157

9.  Cross-receptor interactions between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of dopaminergics.

Authors:  Susanne Koschatzky; Nuska Tschammer; Peter Gmeiner
Journal:  ACS Chem Neurosci       Date:  2011-04-11       Impact factor: 4.418

Review 10.  Optical probes based on G protein-coupled receptors - added work or added value?

Authors:  A D Stumpf; C Hoffmann
Journal:  Br J Pharmacol       Date:  2015-12-19       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.